GlassScriptPhysician profile
Mahmood I Siddique
NPI 1700976073
$109,589.88
in general payments reported to CMS, 2019-2025
41 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,705 · 2020: $15K · 2021: $20K · 2022: $21K · 2023: $19K · 2024: $14K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Honoraria: $12K · Food and Beverage: $4,771 · Travel and Lodging: $2,362 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,431.25 |
| Honoraria | $12,100.00 |
| Food and Beverage | $4,770.66 |
| Travel and Lodging | $2,362.16 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $72,049.03 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Allergan, INC. | $18,601.46 | 2019-2022 | |
| Axsome Therapeutics, INC. | $14,239.14 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Astrazeneca Pharmaceuticals LP | $1,441.09 | 2019-2025 | Fasenra, Farxiga |
| Novo Nordisk INC | $650.08 | 2019-2025 | Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.86 | 2019-2025 | Xifaxan |
| Harmony Biosciences LLC | $385.50 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $272.44 | 2019-2025 | Xywav |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $263.18 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $251.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Ironshore Pharmaceuticals INC. | $162.55 | 2023 | Jornay Pm |
| Depuy Synthes Sales INC. | $92.31 | 2019-2025 | Peak, Monovisc, Orthovisc |
| Merck Sharp & Dohme LLC | $83.35 | 2019-2020 | |
| Lundbeck LLC | $80.11 | 2023-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $69.66 | 2019-2022 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmood Siddique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.